Novartis sets eyes on newly-acquired Alexion with breakthrough tag for rare disease hopeful iptacopan
For years, Alexion’s rare-disease portfolio that centered on C5 inhibitor Soliris has held its grip on a group of profitable ultra-rare indications. But challengers are …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
